More knowledge is therefore needed to better understand the clinical relevance of genetic variability in CYP2D6 metabolism for clinical outcomes in early breast cancer patients subject to tamoxifen treatment, especially in a modern clinical setting with patients receiving multimodal adjuvant therapy. The gene discussed is CYP2D6; the disease is breast carcinoma.